Inclusion Criteria:

Adults ≥ 50 years

• Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year
• BCVA >= 20/400 in the study eye using ETDRS
• Willingness and ability to comply with regular visits
• Signed informed consent

Exclusion Criteria:

• Any surgical treatment of the eye within 3 months prior to baseline in the study eye
• History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)
• Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye
• Retinal pigment epithelial tear involving the macula in the study eye